Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2025-05-21 Director's Dealing
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
Lytix Biopharma AS: GRANT OF SHARE OPTIONS
Director's Dealing Classification · 98% confidence The document is titled "Lytix Biopharma AS: GRANT OF SHARE OPTIONS" and details the allocation of 420,000 share options to primary insiders (Chairperson and Board members) following the 2025 Annual General Meeting. This content directly relates to transactions involving company shares by directors and executives, which falls under the definition of Director's Dealing (insider trades). The filing explicitly mentions compliance with the Norwegian Securities Trading Act and MAR Article 19, typical for insider transaction disclosures. Therefore, the appropriate code is DIRS.
2025-05-21 English
Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress
Investor Presentation Classification · 98% confidence The document is titled 'Q1 2025 results presentation' and contains detailed highlights for the first quarter, including clinical trial updates (Verrica/BCC, NeoLIPA, ATLAS-IT-05) and business updates (leadership changes, board election). This structure—a presentation summarizing recent quarterly performance, clinical progress, and corporate governance changes—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or an Earnings Release (ER) which typically contains only the summary financial tables. Since it is a presentation deck detailing results and strategy, IP is the most appropriate classification.
2025-05-15 English
Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress
Earnings Release Classification · 100% confidence The document is explicitly titled 'Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress' and begins with 'Lytix Biopharma AS, a clinical-stage immuno-oncology company, today announced its results for the first quarter of 2025.' This clearly indicates the release of periodic financial results for a period shorter than a year (Q1). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it mentions management appointments and AGM elections, the primary focus and announcement driver is the quarterly financial results release. Q1 2025
2025-05-15 English
Lytix Biopharma: Invitation to Q1 2025 Results Presentation
Report Publication Announcement Classification · 93% confidence The document is an invitation detailing the date, time, and format (live webcast presentation and Q&A) for the release of Lytix Biopharma's Q1 2025 financial results. It explicitly mentions key personnel (CEO, CFO) and the introduction of a new Chair. This content is characteristic of an announcement preceding an earnings call or results discussion, which aligns best with the 'Call Transcript' (CT) definition if the transcript were present, or the 'Earnings Release' (ER) if it contained the results summary. However, since this document is purely an invitation to a presentation where results will be discussed, and it is very short (2050 chars), it functions as an announcement about an upcoming event where financial results will be presented. The closest fit among the provided options for an announcement about an upcoming results presentation/call is 'Call Transcript' (CT) if we interpret it as the precursor to the call, or 'Earnings Release' (ER) if we consider the event itself to be the primary release mechanism. Given the focus on the 'live webcast presentation' and Q&A, it is most closely related to the event that generates a Call Transcript (CT). However, if the actual results summary (ER) is not present, and this is just the invitation, it could also be seen as a general announcement. Since the event is explicitly about discussing the 'financial results,' ER is a strong candidate, but CT covers the event itself. Given the structure, which is an invitation to a presentation/call, and not the actual results summary (ER) or the transcript (CT), the best fit is often the category that covers the event itself or the immediate precursor. Since the document announces the event where results will be discussed, and it is not the actual report (10-K, IR) or the summary (ER), I will classify it as related to the call event, which is CT, or potentially RNS if it were purely administrative. Because it centers on the 'Results Presentation' and Q&A, it is highly related to the earnings call process. I will select CT as it pertains to the presentation/call event itself, even though it's the invitation rather than the transcript.
2025-05-09 English
Lytix Biopharma: Invitation to Q1 2025 Results Presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'Lytix Biopharma: Invitation to Q1 2025 Results Presentation'. It explicitly states that the company 'will release its first quarter 2025 financial results on Thursday, May 15th, 2025' and invites stakeholders to a 'live webcast presentation' to discuss these results. This is an announcement about an upcoming event where financial results will be discussed, not the actual detailed financial report (which would be an IR or ER) nor the transcript of the call itself (CT). Since it is an invitation/announcement related to the release of periodic financial results, it is best classified as a Report Publication Announcement (RPA), as it announces the publication/discussion of the Q1 results.
2025-05-09 English
Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New Board of Directors
AGM Information Classification · 100% confidence The document is explicitly titled "PROTOKOLL FRA ORDINÆR GENERALFORSAMLING" (MINUTES FROM ANNUAL GENERAL MEETING) in both Norwegian and English. It details the proceedings, resolutions passed (like approval of annual accounts, dividend decisions, board elections, and authorization for capital increases), and the date of the meeting (April 29, 2025). This content perfectly matches the definition of materials shared during an Annual General Meeting.
2025-04-29 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.